We are live on ! Find out more
ARCT icon

Arcturus Therapeutics

37 hedge funds and large institutions have $89.2M invested in Arcturus Therapeutics in 2015 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

16% more funds holding

Funds holding: 3237 (+5)

7% more capital invested

Capital invested by funds: $83.2M → $89.2M (+$6.05M)

31% less call options, than puts

Call options by funds: $272K | Put options by funds: $395K

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
37
Holders Change
+5
Holders Change %
+15.63%
% of All Funds
1.03%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
10
Increased
12
Reduced
9
Closed
5
Calls
$272K
Puts
$395K
Net Calls
-$123K
Net Calls Change
-$556K

ARCT Hedge Fund Activity: Q3 2015 in Review

37 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2015, worth a combined $89.2M — up 7.3% from $83.2M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ARCT positions and 5 closed out — a net gain of 5 holders — while 12 added to existing stakes and 9 trimmed.

The largest buyer was Hayman Capital Management, opening a new position worth an estimated $4.7M. The largest seller was Baker Bros. Advisors, cutting an estimated $1.13M.

  • 37 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2015, up from 32 in Q2 2015.
  • Funds reported $89.2M of Arcturus Therapeutics stock for Q3 2015, up 7.3% quarter-over-quarter.
  • 10 funds opened new Arcturus Therapeutics positions in Q3 2015 and 5 closed out, a net change of +5 holders.
  • The largest Arcturus Therapeutics buyer in Q3 2015 was Hayman Capital Management, an estimated $4.7M added.
  • The largest Arcturus Therapeutics seller in Q3 2015 was Baker Bros. Advisors, an estimated $1.13M sold.

Based on aggregated 13F filings for Q3 2015.